SalaryGuide
AboutPricingFor Employers

Marketing jobs

7 marketing jobs

Lilly logo
4 days ago

Senior Director – Creative & Production, Global Communications

Lilly

Indianapolis, IN (On-site)Full time$155K/yr – $227K/yr
Lilly logo
8 days ago

Associate Director, Oncology Communications

Lilly

Indianapolis, IN (Remote)Full time$128K/yr – $187K/yr
Lilly logo
8 days ago

Associate - Search Engine Optimization

Lilly

Indianapolis, IN (On-site)Full time$59K/yr – $138K/yr
Lilly logo
9 days ago

Senior Director, Global Consumer Science Communications

Lilly

Indianapolis, IN (Hybrid)Full time$155K/yr – $227K/yr
Lilly logo
7 weeks ago

Senior Director, Zepbound Consumer Marketing

Lilly

Indianapolis, IN (On-site)Full time$155K/yr – $227K/yr
Lilly logo
4 months ago

Global Marketing Director (P4-P5)

Lilly

Indianapolis, IN (On-site)Full time
Lilly logo
4 months ago

Associate Director, Media Strategy

Lilly

Indianapolis, IN (On-site)Full time$128K/yr – $187K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

7 jobs
Lilly logo

Senior Director – Creative & Production, Global Communications

Lilly

Indianapolis, IN (On-site)

$155K/yr - $227K/yrIn-houseFull-timeSenior level10+ years exp.
4 days ago
Lilly logo

Associate Director, Oncology Communications

Lilly

Indianapolis, IN (Remote)

$128K/yr - $187K/yrIn-houseFull-timeMid level5+ years exp.
8 days ago
Lilly logo

Associate - Search Engine Optimization

Lilly

Indianapolis, IN (On-site)

$59K/yr - $138K/yrIn-houseFull-timeEntry level1+ years exp.
8 days ago
Lilly logo

Senior Director, Global Consumer Science Communications

Lilly

Indianapolis, IN (Hybrid)

$155K/yr - $227K/yrIn-houseFull-timeSenior level8+ years exp.
9 days ago
Lilly logo

Senior Director, Zepbound Consumer Marketing

Lilly

Indianapolis, IN (On-site)

$155K/yr - $227K/yrIn-houseFull-timeSenior level8+ years exp.
7 weeks ago
Lilly logo

Global Marketing Director (P4-P5)

Lilly

Indianapolis, IN (On-site)

In-houseFull-timeSenior level3+ years exp.
4 months ago
Lilly logo

Associate Director, Media Strategy

Lilly

Indianapolis, IN (On-site)

$128K/yr - $187K/yrIn-houseFull-timeSenior level7+ years exp.
4 months ago
Lilly logo
Lilly

Senior Director – Creative & Production, Global Communications

Indianapolis, IN (On-site)

$155K/yr – $227K/yrSenior Level10+ years expFull time

Posted 4 days ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own and guide Global Communications' creative vision, build and lead an in-house studio, scale production through a network of partners, and drive emotionally compelling storytelling across channels, while advancing technology and archival storytelling assets.

  • Lead creative direction and brand storytelling across platforms
  • Build, manage, and scale an in-house studio and external partnerships
  • Collaborate across teams to translate strategy into campaigns and leadership creative

Job Description

Responsibilities

  • Set the creative vision and direction for Global Communications — partnering with the masterbrand team to carry Lilly’s visual identity into everything we make and evolve how the brand shows up in storytelling.
  • Concept and produce social-first, channel-native content in close partnership with the Senior Director, Digital & Social Media — bringing the editorial vision and calendar to life across LinkedIn, Instagram, X, Facebook, YouTube, and Lilly.com.
  • Build and lead an in-house creative studio across video, design, and multimedia that produces against the editorial calendar and in real time as moments emerge — at newsroom pace, without compromising craft.
  • Attract, develop, and retain top creative talent, building a high-standards culture with the clear expectations and psychological safety for people to take real creative risks.
  • Champion storytelling excellence across Global Communications — finding the human truth in complex science and strategy and shaping it into clear, emotionally compelling narratives that connect Lilly's work to the people it's for.
  • Push creative boundaries with new technology — integrating automation, generative and agentic AI, and intelligent workflows that increase speed, precision, and consistency.
  • Own how creative moves through the pipeline — the project tracking, milestone management, and operating rhythms that keep work efficient, on time, and visible to leadership.
  • Scale production beyond the in-house team — building and stewarding a network of agencies and freelance creatives, and partnering closely with Thread Collective, Lilly’s in-house agency, on execution, shared resources, and budget.
  • Activate Lilly’s history as a strategic storytelling asset, leading the historians and archivists who preserve it and bring it into narratives that resonate with diverse audiences.
  • Partner across Global Communications — with Enterprise and Executive Communications, Workforce Engagement, and therapeutic area and business unit teams — to translate strategy into campaign, launch, and leadership creative.

Requirements

  • Bachelor's degree in marketing, communications, advertising, journalism, design, or a related creative field.
  • 10+ years of creative and leadership experience within a corporate, agency, or global communications environment, with deep experience in consumer brand, retail, sportswear, ecommerce, healthcare/pharma, or other high-velocity consumer categories.
  • Qualified applicants must be authorized to work in the United States on a full-time basis. Lilly will not provide support for or sponsor work authorization or visas for this role, including but not limited to F-1 CPT, F-1 OPT, F-1 STEM OPT, J-1, H-1B, TN, O-1, E-3, H-1B1, or L-1.

Preferred

  • Experience creating strategic, channel-native social media content optimized for performance across platforms such as LinkedIn, Instagram, TikTok, X, and YouTube.
  • Validated experience in a fast-paced newsroom or newsroom-style environment, where speed, editorial judgment, and reputation pressure are constant.
  • Additional experience in a regulated/healthcare organization or high-profile consumer brand environment is a strong plus.
  • Extensive portfolio demonstrating creative excellence across various media, including video, design, and multimedia, with a focus on enterprise storytelling.
  • Experience using data and insights to inform creative strategy and evaluate content impact.
  • Deep technical expertise in design software (Adobe Creative Suite) and proficiency with emerging AI-powered design tools.

Benefits

  • Lilly offers a comprehensive benefit program to eligible employees, including eligibility to participate in a company-sponsored 401(k); pension; vacation benefits; eligibility for medical, dental, vision and prescription drug benefits; flexible benefits (e.g., healthcare and/or dependent day care flexible spending accounts); life insurance and death benefits; certain time off and leave of absence benefits; and well-being benefits (e.g., employee assistance program, fitness benefits, and employee clubs and activities).
  • Lilly reserves the right to amend, modify, or terminate its compensation and benefit programs in its sole discretion and Lilly’s compensation practices and guidelines will apply regarding the details of any promotion or transfer of Lilly employees.
Lilly logo

Lilly

🚀 Lilly - La Révolution du Recrutement Automatisé ! 🚀Simplifiez votre sourcing, boostez votre productivité et trouvez les meilleurs talents en un temps record ! 🔍Avec Lilly, vous pouvez : 💡 Automatiser la recherche et la sélection des meilleurs candidats. ⚡ Lancer votre sourcing en moins de 60 secondes. 🎯 Identifier les talents parfaits grâce à une technologie de pointe en IA. 💬 Envoyer des messages personnalisés et engageants automatiquement. 📈 Optimisez vos recrutements et réduisez le temps passé à chercher des candidats.L'essai est 100% gratuit et vous permet de découvrir à quel point votre recrutement peut être plus rapide, intelligent, et efficace.Vous êtes une agence, une start-up, un ESN ou une entreprise en croissance ? Lilly est faite pour vous !💥 Rejoignez la révolution du recrutement dès maintenant ! 💥

1 employees
lilly-recruiter.com

Headcount Trend

Current headcount: ~1

Marketing Team

Median Tenure
29.6 years
Marketing Roles Posted (Last 30 Days)
6

People

Founders / CEO

Lilly KipLee
Lilly KipLee
CEO and Founder
At the company for 10 years

HR / Recruitment

Ryan Burke
Ryan Burke
Talent Acquisition - HR Global Recruiting & Staffing
At the company for 35 years 7 months

Recent News

Eli Lilly to build $6 billion Alabama plant as part of US manufacturing push
Dec 10, 2025 • Reuters
Eli Lilly announces $6 billion pharmaceutical manufacturing investment in Huntsville
Dec 9, 2025 • City of Huntsville (.gov)
Governor Ivey Announces Pharmaceutical Giant Lilly Plans $6 Billion Advanced Manufacturing Plant in Huntsville
Dec 9, 2025 • Alabama Governor's Office (.gov)
Eli Lilly Plans $6 Billion Investment, 450 Jobs In Huntsville
Dec 9, 2025 • Huntsville Business Journal
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Dec 9, 2025 • Eli Lilly and Company
Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugs
Dec 9, 2025 • CNBC
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in Alabama
Dec 9, 2025 • PR Newswire
Lilly and IU to expand access to clinical trials and latest innovative treatments for Hoosiers
Dec 3, 2025 • News at IU
Lilly lowers the price of Zepbound® (tirzepatide) single-dose vials | Eli Lilly and Company
Dec 1, 2025 • Eli Lilly and Company
Eli Lilly unveils new direct-to-employer model for weight loss drugs
Nov 21, 2025 • Fierce Healthcare
Lilly becomes first drugmaker to hit $1 trillion valuation on weight-loss demand
Nov 21, 2025 • Reuters
Lilly announces plans to open Lilly Gateway Labs site in Philadelphia
Nov 19, 2025 • PR Newswire
Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans
Nov 6, 2025 • Eli Lilly and Company
White House announces deals with Eli Lilly, Novo Nordisk to lower drug costs
Nov 6, 2025 • American Hospital Association
Lilly plans to build a new $3 billion facility to boost oral medicine manufacturing capacity in Europe for patients worldwide | Eli Lilly and Company
Nov 3, 2025 • Eli Lilly and Company
Eli Lilly’s weight loss and diabetes drug tops Keytruda as world’s best-selling medicine
Oct 30, 2025 • statnews.com
Lilly reports third-quarter 2025 financial results, highlights R&D pipeline momentum and raises 2025 guidance
Oct 30, 2025 • Eli Lilly and Company
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States | Eli Lilly and Company
Oct 29, 2025 • Eli Lilly and Company
Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States
Oct 29, 2025 • PR Newswire
Eli Lilly to invest $1.2 billion in Puerto Rico as part of US manufacturing push
Oct 29, 2025 • Reuters
Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients | Eli Lilly and Company
Oct 28, 2025 • Eli Lilly and Company
Eli Lilly, NVIDIA team up to build pharma’s biggest AI supercomputer
Oct 28, 2025 • statnews.com
Lilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial | Eli Lilly and Company
Oct 24, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, demonstrated superior glycemic control in two successful Phase 3 trials, reconfirming its potential as a foundational treatment in type 2 diabetes | Eli Lilly and Company
Oct 15, 2025 • Eli Lilly and Company
Eli Lilly’s strategy in motion: Beyond diabetes and obesity
Sep 24, 2025 • Labiotech.eu
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Sep 23, 2025 • PR Newswire
Eli Lilly to make weight-loss pill in new $6.5 billion Texas plant
Sep 23, 2025 • Reuters
Governor Abbott Announces New Eli Lilly Manufacturing Investment In Harris County
Sep 23, 2025 • Office of the Texas Governor (.gov)
Lilly plans to build a new $6.5 billion facility to manufacture active pharmaceutical ingredients in Texas
Sep 23, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, demonstrated meaningful weight loss and cardiometabolic improvements in complete ATTAIN-1 results published in The New England Journal of Medicine
Sep 16, 2025 • Eli Lilly and Company
Lilly unveils 1st of 4 new US manufacturing sites with $5B Virginia API plant
Sep 16, 2025 • Fierce Pharma
Drug manufacturer Eli Lilly to build plant in Goochland, create 650 permanent jobs
Sep 16, 2025 • Virginia Mercury
Lilly trial shows weight loss with experimental pill flattens over time
Sep 16, 2025 • Reuters
Lilly launches TuneLab platform to give biotechnology companies access to AI-enabled drug discovery models built through over $1 billion in research investment
Sep 9, 2025 • Eli Lilly and Company
Eli Lilly temporarily halts UK shipments of weight-loss drug Mounjaro
Aug 27, 2025 • Reuters
Lilly's Verzenio® (abemaciclib) increases overall survival in HR+, HER2-, high-risk early breast cancer with two years of therapy | Eli Lilly and Company
Aug 27, 2025 • Eli Lilly and Company
Anne White to Retire as Executive Vice President and President, Lilly Neuroscience
Aug 20, 2025 • Eli Lilly and Company
Lilly shares fall as obesity pill misses expectations in key trial
Aug 7, 2025 • BioPharma Dive
Lilly raises full-year earnings forecasts on surging demand for weight-loss drug
Aug 7, 2025 • Reuters
Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity | Eli Lilly and Company
Aug 7, 2025 • Eli Lilly and Company
Wisconsin offering up to $100M in development incentives to Eli Lilly's Kenosha County project
Aug 5, 2025 • WPR
Lilly's Mounjaro (tirzepatide), a GIP/GLP-1 dual agonist, demonstrated cardiovascular protection in landmark head-to-head trial, reinforcing its benefit in patients with type 2 diabetes and heart disease
Jul 31, 2025 • Eli Lilly and Company
Lilly's Kisunla (donanemab-azbt) showed growing benefit over three years in early symptomatic Alzheimer's disease
Jul 30, 2025 • Eli Lilly and Company
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
Jul 29, 2025 • Eli Lilly and Company
Lilly completes acquisition of Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk | Eli Lilly and Company
Jul 25, 2025 • Eli Lilly and Company
FDA approves updated label for Lilly's Kisunla (donanemab-azbt) with new dosing in early symptomatic Alzheimer's disease | Eli Lilly and Company
Jul 9, 2025 • Eli Lilly and Company
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials | Eli Lilly and Company
Jun 22, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1 medicines, in complete Phase 3 results published in The New England Journal of Medicine
Jun 21, 2025 • Eli Lilly and Company
Lilly partners with Camurus in search of a long-lasting obesity drug
Jun 4, 2025 • BioPharma Dive
Lilly presents first clinical data for its investigational, next-generation FRα targeting ADC in platinum-resistant ovarian cancer at the 2025 ASCO Annual Meeting
Jun 2, 2025 • Eli Lilly and Company
Lilly to expand its pain pipeline with acquisition of SiteOne Therapeutics | Eli Lilly and Company
May 27, 2025 • Eli Lilly and Company
Lilly plans to expand Purdue University collaboration with up to a $250 million investment to accelerate pharmaceutical innovation
May 9, 2025 • Purdue University
Lilly reports first-quarter 2025 financial results and highlights pipeline momentum | Eli Lilly and Company
May 1, 2025 • Eli Lilly and Company
Lilly's oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial
Apr 17, 2025 • Eli Lilly and Company
Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial
Mar 30, 2025 • Reuters
Lilly’s statement about the CHMP opinion issued for donanemab | Eli Lilly and Company
Mar 28, 2025 • Eli Lilly and Company
Lilly plans to more than double U.S. manufacturing investment since 2020 exceeding $50 billion | Eli Lilly and Company
Feb 26, 2025 • Eli Lilly and Company
Lilly expands US manufacturing build-out with $50B target
Feb 26, 2025 • BioPharma Dive
Lilly launches additional Zepbound vial doses and offers new savings for self-pay patients
Feb 25, 2025 • Eli Lilly and Company
FDA approves Lilly's Omvoh® (mirikizumab-mrkz) for Crohn's disease, expanding its use to the second major type of inflammatory bowel disease
Jan 15, 2025 • Eli Lilly and Company
Announcement: Andreessen Horowitz Partners with Lilly to Launch First-of-Its-Kind Biotech Ecosystem Fund
Jan 14, 2025 • Andreessen Horowitz
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Jan 14, 2025 • Reuters
Lilly to acquire Scorpion Therapeutics' mutant-selective PI3Kα inhibitor program | Eli Lilly and Company
Jan 13, 2025 • Eli Lilly and Company